{"id":80709,"date":"2024-05-30T13:22:03","date_gmt":"2024-05-30T13:22:03","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/biognosys-launches-spectronaut-19-and-presents-advances-with-its-research-platforms-at-the-asms-2024-annual-conference\/"},"modified":"2024-05-30T13:22:03","modified_gmt":"2024-05-30T13:22:03","slug":"biognosys-launches-spectronaut-19-and-presents-advances-with-its-research-platforms-at-the-asms-2024-annual-conference","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/biognosys-launches-spectronaut-19-and-presents-advances-with-its-research-platforms-at-the-asms-2024-annual-conference\/","title":{"rendered":"Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; margin-bottom:1.4pt;\">Spectronaut<sup>\u00ae<\/sup> 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows<\/li>\n<li style=\"margin-top:6pt; margin-bottom:1.4pt;\">Novel TrueDiscovery<sup>\u00ae<\/sup> P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics<\/li>\n<li style=\"margin-top:6pt; margin-bottom:1.4pt;\">New TrueTarget<sup>\u00ae<\/sup> high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identification<\/li>\n<li style=\"margin-top:6pt; margin-bottom:1.4pt;\">DigitalProteome\u2122 database and Proteoverse\u2122 data exploration tool help extract biological insights for biopharma research<\/li>\n<\/ul>\n<p>ZURICH, Switzerland and NEWTON, Mass., May  30, 2024  (GLOBE NEWSWIRE) &#8212; Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company\u2019s attendance at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yr33rN_pALPtUGBeVpilStxBJBFvIv4jBb7sdE0tfu31WaxP3umsD262aHX-572MgUcJfK72KDZrnsJHo8oenGmFFkaFJuOgp3WZJwTdKdvet2n532LGpmALHJ32etfw1Y80kbVMbwb2OvCFPsRLTh_PdWyU0O87O5Xa8RSw2bZIIzxZ0BI1DUWlG-LVXWYw\" rel=\"nofollow noopener\" target=\"_blank\" title=\"American Society for Mass Spectrometry (ASMS) Annual Conference\">American Society for Mass Spectrometry (ASMS) Annual Conference<\/a> from June 2<sup>nd<\/sup> to June 6<sup>th<\/sup> in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions.<\/p>\n<p>Biognosys\u2019 scientific presence includes two breakfast seminars, four oral presentations, and eleven posters. In addition, their team of scientific experts will be present at booth #314. Further, Biognosys will participate in the activities of its strategic partner, Bruker, showcasing a comprehensive ecosystem of proteomics solutions at Bruker\u2019s eXceed Symposia, \u201cMultiomics solutions for the post-genomic era\u201d on Sunday, June 2<sup>nd<\/sup>, and Hospitality Suite from Sunday, June 2<sup>nd<\/sup> until Wednesday, June 5<sup>th<\/sup>.<\/p>\n<p><strong>Spectronaut<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> 19: Unleashing the Power of AI for Deep, Fast, and Scalable DIA Analysis<\/strong><\/p>\n<p>This latest release of Biognosys\u2019 flagship software for DIA analysis comes with significant improvements in peptide and protein level identifications, increased depth of candidates&#8217; discovery rate, scalability for large-scale analysis and enterprise use, and extended support for novel workflows.<\/p>\n<p>\u201cWhile this is one of the feature richest releases we ever had, it\u2019s the improvement in quantification that stands out in Spectronaut 19,\u201d <strong>said<\/strong> <strong>Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys<\/strong>. \u201cWe invested a lot in understanding quantification better, which has clearly paid off. In terms of technologies, improved AI models had a significant impact on this year\u2019s release.\u201d<\/p>\n<p><strong>Jun.-Prof. Dr. Florian Meier-Rosar from University Hospital Jena (UKJ), Faculty of Medicine, stated:<\/strong> \u201cSpectronaut is a great fit for our DIA projects. Its directDIA workflow combines ease of use with reliable quantification which suits our needs when studying protein abundance and post-translational modifications at scale.\u201d<\/p>\n<p><strong>Yansheng Liu, Ph.D., Associate Professor at Yale University School of Medicine, Department of Pharmacology, commented:<\/strong> \u201cSpectronaut is our preferred DIA analysis software due to its high performance and user-friendly interface, which makes analyzing our complex and multiplex DIA datasets both easy and reliable.\u201d<\/p>\n<p>Biognosys\u2019 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lyeYHWNtDLDRUYNKjIzme4xdLbAilxHfLRmDrFZMtZNyhepa8OzQwC-SvLb_jVZcOQYDhbsKpLR972iLzdsvZcpY3Ik6OoGHLxOsncmW0YeKsRR0kx_EIN33tM7rBc4si-3qpjC50NrBELDLdxCGRX53akxgwwTBdEougVNxFfWKoK-JNbomWNgzYjn9sl3YDynYpHjA4E0up07DNa7Hjw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Breakfast Seminar, \u201cSpectronaut 19: Unlock your data\u2019s true story\u201d\">Breakfast Seminar, \u201cSpectronaut 19: Unlock your data\u2019s true story\u201d<\/a> on Tuesday, June 4<sup>th<\/sup>\u00a0is entirely dedicated to this release, featuring presentations by Prof. Josh Coon from University of Wisconsin-Madison, titled \u201cSingle-Shot DIA Proteome Analysis: The New Gold Standard for Quantitative Proteomics\u201d, and Denys Oliinyk from Jena University Hospital, titled \u201cTowards High-dimensional Phosphoproteomics with Data-independent Acquisition and \u00b5Phos\u201d. In addition, the company will present\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qr8uzyA0lm8hwsreDYBDMaEMqKH64b0hRWDUQVWMMxR4ddXAvae46tewCENSaULxvGQDMTs_91-PgPQnNEJwg1sy6gKlC94Nal0IBBuDFRaSmxD-QZfG6t0nFcrdygfTnC-4aeTID4XVAnX5mF93ww==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"3 orals and 3 posters\">3 orals and 3 posters<\/a>\u00a0highlighting recent improvements in Spectronaut.<\/p>\n<p><strong>TrueDiscovery<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong>: now enhanced with groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics<\/strong><\/p>\n<p>Biognosys is launching a novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type based enrichment with market-leading performance and superior economics. The method offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological, or population proteomics research. The P2 Plasma Enrichment workflow will be available as a CRO service via Biognosys\u2019 TrueDiscovery<sup>\u00ae<\/sup> platform, or as an in-house method for high-performance mass spectrometry end-users via licensing.<\/p>\n<p>The technical features and performance data will be presented on Wednesday, June 5<sup>th<\/sup> during the WP 084 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FWeFmUFcztKacg6QasIZpVcij1sj7fdGKgg4t6Tji5Mcwaz1DFBIQP1nMy-s3Fvx6BelvdMknCUDFY0NRGDIIBpZ4K3u9jk7D5vjiomOtsDLp325z9m8hyUB0e1ic0DY\" rel=\"nofollow noopener\" target=\"_blank\" title=\"poster session\">poster session<\/a> and on Monday, June 3<sup>rd<\/sup> during Biognosys\u2019 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lyeYHWNtDLDRUYNKjIzme4xdLbAilxHfLRmDrFZMtZNKEio6NsxvpiMKGI0P1O0R9HxjXDZ3irYobEWcZkuPDczHu4ak4k1b2ZyA6PyL3Q21an1Fdv1vAHFFXFbIx66Si1vshjDiCbCA86n0FvkV50-FHNpWTQq9x6sA-vzzvYb_Gg3P9456Ks-ZPK-Oofqhp8IJZBf-0_Wk5UsMrrHCXoxW1wp223S6CODjX3h43EwuI6HU4aXYG3vb7D-0agOYmi3ZPK6RymW4FV10OINejSjygLs4JsrQ_9XtBMhMKGNNlVFxDOYnEvP6q-iSJ1pk45w7R0WGkBxMPLlki1FU8Q==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Breakfast Seminar, \u201cAccelerating Drug Discovery and Development with Biognosys\u2019 Next-Generation Proteomics Services\u201d\">Breakfast Seminar, \u201cAccelerating Drug Discovery and Development with Biognosys\u2019 Next-Generation Proteomics Services\u201d<\/a>. This seminar also features presentations by Eric Kuhn from Kymera Therapeutics on \u201cMass Spectrometry-Based Approaches to Targeted Protein Degradation Drug Discovery and Development\u201d and Alan Shomo from Biogen on \u201cDevelopment of a Quantitative CSF LRRK2 Assay to Support Clinical Studies\u201d.<\/p>\n<p><strong>TrueTarget<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong>: introducing a high-throughput workflow for large-scale drug target deconvolution screening<\/strong><\/p>\n<p>A critical challenge in drug development is the high failure rate of candidate drugs in clinical trials. Identifying drug targets and potential off-targets efficiently is crucial. Biognosys&#8217; TrueTarget<sup>\u00ae<\/sup> platform, powered by limited proteolysis mass spectrometry (LiP-MS), is a powerful tool for unbiased drug target identification, that is available both as contract research service and licensing option. To facilitate its use for large-scale screening, Biognosys developed an innovative, LiP-MS-HT protocol for automated high-throughput drug target deconvolution that achieves improved target identification and reduced measurement time, with high reproducibility and quantitative precision. Biognosys will present the new LiP-MS-HT workflow during the ThOH <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M1rkQWVTI32n7OZ_d0UdDEQ89NTFBz3xRRMZeVRHeEPNZ0Ss8qnhyjZTJgZbxVpj3VCDA2gydYXDspBx4ITNhjAP1_Jl5e5dTjkSvr6pU5WMpeyeXVoBUOGtRdXywvB5Yvamd_aXx3VjOkWl5fcIBA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Oral Session\">Oral Session<\/a> on Thursday, June 6<sup>th<\/sup>.<\/p>\n<p><strong>DigitalProteome\u2122 and Proteoverse\u2122: turning data into biological insights for biopharma research <\/strong><\/p>\n<p align=\"justify\">Biognosys\u2019 new data insights solution, DigitalProteome\u2122, provides valuable insights into protein expression and significantly enhances in-vivo biomarker discovery and drug development studies. The database includes proteome profiles from 22 healthy tissues from humans, mice, and rats and is readily available as an off-the-shelf library. The key characteristics of the DigitalProteome\u2122 database will be presented on Wednesday, June 5th during the WP 070 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FWeFmUFcztKacg6QasIZpSo3-9CCI0y01I3EqFFsfbpybTLtllSGzSOt3D9JktW27qC8Cfb9f8EogQMoUIkCqj00lObZvmWebqTTsI0Yo8hz-C6kvYVRZeYHWsI_jDF2\" rel=\"nofollow noopener\" target=\"_blank\" title=\"poster session\">poster session<\/a>. The resource is available for biopharma research via licensing.<\/p>\n<p>To make the rich mass spectrometry data produced by Biognosys&#8217; research service platforms even more accessible and actionable, customers can access the novel Proteoverse\u2122 platform for data visualization and exploration to swiftly extract valuable biological insights, identify key analytes from thousands of proteins, explore peptide-level structures, and examine their biological relevance. The tool will be presented on Thursday, June 6<sup>th<\/sup> during the ThP 119 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FWeFmUFcztKacg6QasIZpdGTCSYjAA-YBUQsWH6HNboP3DkCUmKkQGS93vyAmlGG0PyEWZtdzbyOs_kXN0E4qp9Fnn6yDzMPIazw6WFyBIjm10EBJd_moBTpjLyIXZUh\" rel=\"nofollow noopener\" target=\"_blank\" title=\"poster session\">poster session<\/a>. The tool is initially available as a free-of-charge service alongside Biognosys&#8217; TrueDiscovery<sup>\u00ae<\/sup> research projects.<\/p>\n<p>Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fQYdtSWqwbyni7WU8QBnqtN-xjOrga8q22D8cmwgkUmJTV_zgI3SwiGDa7cWg4KC67_F8evAF7SpuLRG5GEmaCL6go-Dw_UvkL19z_73JhtdvTjJEIViEcorH-HUafukm6KFe_rk0efGrMARx8bsCg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/biognosys.com\/asms2024<\/a> for a complete overview of Biognosys\u2019 presence at ASMS. Posters will be available for download by Friday, June 7.<\/p>\n<p><strong>About Spectronaut<sup>\u00ae<\/sup><\/strong><\/p>\n<p>Spectronaut is Biognosys\u2019 flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.<\/p>\n<p>The software employs advanced Search and Artificial Intelligence (AI) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multi-dimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vNI6bvVvp_2Scx2lT5YIAMtalx6xSWlaE38ayEiF1OEGnbWlVwXuwiqs4ZBkl_4IqhRUEy1kPm9etTl9kgLjG0CFrtX2YiAM3o05G-dieOM=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>spectronaut.com<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>About TrueDiscovery<\/strong><sup><strong>\u00ae<\/strong><\/sup><\/p>\n<p>The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.<\/p>\n<p>TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.<\/p>\n<p>TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GCP compliant environment. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yuMLSx5byLYENCs4M_MnZs4KQ1GCjVdAarJuuQfJhxA0VjmOPh_N0GFGCnH3-cjlz3vNqkf5WEuqRYMhl9Nv-0KVe0mRmJ2WLiY3cI1dLV8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>truediscovery.bio<\/u><\/a>.<\/p>\n<p><strong>About TrueTarget<sup>\u00ae<\/sup><\/strong><\/p>\n<p>The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.<\/p>\n<p>TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget\u2122 is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.<\/p>\n<p>The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yuMLSx5byLYENCs4M_MnZqbdQ3cflbnv3J6hIgoGwfJ2HeKjmjKJyVfc5QYiuUStiP2vVTAzfKXzFqwhM4PWXA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"truetarget.bio\">truetarget.bio<\/a>.<\/p>\n<p align=\"justify\"><strong>About Biognosys<\/strong><\/p>\n<p>At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery<sup>\u00ae<\/sup>, TrueTarget<sup>\u00ae<\/sup>, and TrueSignature<sup>\u00ae<\/sup> research service platforms, our flagship software Spectronaut<sup>\u00ae<\/sup>, and the PQ500\u2122 kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qIQgKQjreSVoCO1RXtCvypwa44cIxdfdqgqumzsi5I6Dvjz7uoJVlnaE_taT8HM5DiLWXbbsSZFTcGXLZYyR36cafti7HYEIta93oWeQgiE=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>biognosys.com<\/u><\/a>.<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fQYdtSWqwbyni7WU8QBnqv6w6bfKLJVB-MAgF6P3FxdQlirSjuOxfK3A4VRGbkw6EOOngvEB8uYyHm97LWbt-TvZpckkccEIoEJD3lDPQLrpIfKLK5eLgkWycZGibvZo7e5ZVbRoLmVPppZnuXyrrYaM8UtwEs6k6ATFFuJF--EHyP5IFFzJo414cxoQCAYXY_NgrAlJKNsJrFePognNxRCjtR8B16C5uM5yIHaihxZv4dZZQjKxkf9DEbsOEXcoaSBvplge3kcomrN6UwuvKA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/940b0780-73b6-4c45-84f0-3541e3539ee7<\/a><\/p>\n<pre\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Spectronaut\u00ae 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows Novel TrueDiscovery\u00ae P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics New TrueTarget\u00ae high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identification DigitalProteome\u2122 database and Proteoverse\u2122 data [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":80710,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/f0297835-1fc4-4c42-b127-ee08aa55e153","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-80709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/80709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=80709"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/80709\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/80710"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=80709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=80709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=80709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}